-$0.10 Earnings Per Share Expected for ContraFect Corp (CFRX) This Quarter

Equities analysts expect ContraFect Corp (NASDAQ:CFRX) to post earnings of ($0.10) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ContraFect’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.10). ContraFect posted earnings per share of ($0.15) in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.

On average, analysts expect that ContraFect will report full year earnings of ($0.33) per share for the current fiscal year, with EPS estimates ranging from ($0.33) to ($0.32). For the next year, analysts expect that the company will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.45) to ($0.35). Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover ContraFect.

ContraFect (CFRX) opened at $1.50 on Tuesday. ContraFect has a 52 week low of $0.80 and a 52 week high of $2.50.

Institutional investors have recently added to or reduced their stakes in the business. Birchview Capital LP increased its stake in ContraFect by 56.5% during the 3rd quarter. Birchview Capital LP now owns 1,135,082 shares of the biotechnology company’s stock valued at $1,260,000 after buying an additional 410,000 shares during the period. 683 Capital Management LLC acquired a new position in ContraFect during the 3rd quarter valued at about $2,886,000. Finally, Fosun International Ltd acquired a new position in ContraFect during the 3rd quarter valued at about $9,435,000. 62.51% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “-$0.10 Earnings Per Share Expected for ContraFect Corp (CFRX) This Quarter” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/13/0-10-earnings-per-share-expected-for-contrafect-corp-cfrx-this-quarter.html.

ContraFect Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Get a free copy of the Zacks research report on ContraFect (CFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply